Amgen Raises Forecast for Year Even as Biosimilars Encroach

(Bloomberg) -- Amgen Inc., maker of the blockbuster arthritis treatment Enbrel, saw sales drop in the second quarter as newer drugs struggled and biosimilars threatened the company’s older portfolio.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.